BTK inhibitor 16 [PMID: 30122225]   Click here for help

GtoPdb Ligand ID: 10076

Synonyms: example 90 [US20160264548]
Compound class: Synthetic organic
Comment: This compound is reported as an irreversible, covalent inhibitor of Bruton's tyrosine kinase (BTK) [2]. It is compound 23 (example 90) as claimed in Merck's patent US20160264548A1 [1].
Because of its expression pattern on B cells, macrophages, neutrophils, and monocytes (NOT T cells) and its essential role in B lymphocyte development and function, BTK continues to be investigated as a valid therapeutic target for the treatment of diseases that involve B-cell and/or macrophage activation (e.g. B-cell malignancies, asthma and rheumatoid arthritis). Ibrutinib was the first-in-class small molecule BTK inhibitor to reach the clinic. Unfortunately, ibrutinib causes severe adverse effects that are in the main, attributed to its off-target profile. As a result, second-generation BTK inhibitors with optimised structures and improved selectivity are being developed. Inhibitor 16 described here, exhibits comparable cellular potency to ibrutinib but has a higher kinome selectivity against undesirable off-targets.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 97.99
Molecular weight 456.18
XLogP 4.35
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C=CC(=O)N1CC2CC1CN2c1ccc(c(n1)Oc1ccc(cc1)Oc1ccccc1)C(=O)N
Isomeric SMILES C=CC(=O)N1C[C@@H]2C[C@H]1CN2c1ccc(c(n1)Oc1ccc(cc1)Oc1ccccc1)C(=O)N
InChI InChI=1S/C26H24N4O4/c1-2-24(31)30-16-17-14-18(30)15-29(17)23-13-12-22(25(27)32)26(28-23)34-21-10-8-20(9-11-21)33-19-6-4-3-5-7-19/h2-13,17-18H,1,14-16H2,(H2,27,32)/t17-,18-/m0/s1
InChI Key FVEYIFISRORTDD-ROUUACIJSA-N
Bioactivity Comments
In freshly isolated human peripheral blood mononuclear cells inhibitor 16 reduced a BTK-mediated B cell receptor downstream signalling event (anti-IgM-induced expression of CD69) with an IC50 of 9.7 nM [2]. In a kinase selectivity screen inhibitor 16 inhibited 4 of 270 kinases tested by >50% at 1 μM (BTK (98%), Blk (96%), BMX (95%), Txk (54%)). In comparison, ibrutinib inhibited 35 of the 270 kinases by >50% at the same concentration. Inhibitor 16 inhibits the hERG channel with a Ki of 2.2 μM. It is an unfavouably potent inhibitor of CYP450 2C8.
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Bruton tyrosine kinase Primary target of this compound Hs Inhibitor Inhibition 9.1 pIC50 - 2
⤷ pIC50 9.1 (IC50 7x10-10 M) [2]
Description: Using a microfluidic, off-chip mobility shift kinase assay with FITC-AHA-EEPLYWSFPAKKK-NH2 as peptide substrate.